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Abstract
Background: Hepatitis B virus infection although preventable by vaccination remains an important
health issue throughout the world due to its morbidity, mortality and economical losses. Early
seroprotection is desirable for people at high risk of exposure. The aim of this study was to
determine whether three-week hepatitis B vaccination (on days 0, 10 and 21) provide
seroprotection or not.
Methods: The 120 subjects enrolled into the study were divided into two groups and vaccinated
by the classic (months 0, 1, and 2) or the accelerated (days 0, 10, and 21) schedules and antibody
response determined on days 30, 60, and 90 and, if below 10 mIU/ml-1, again on day 180. For each
individual in the classic group (B) three subjects were enrolled in the accelerated group (A).
Recombinant hepatitis B vaccine (Gen-Hevac B, Pasteur) was given as 20 micrograms intramuscular
injections via the deltoid muscle. A booster dose on day 365 was administered for each group.
Family members of hepatitis B carriers and volunteer health personnel were enrolled into group
A. To the B group only volunteers who wanted vaccination against hepatitis B were included.
Results: After three doses of vaccine, Anti-HBs titers reached protective levels in both groups.
The number of vaccinees with seroprotective levels of Anti-HBs (≥10 mIU/ml-1) on day 30 was 53
(58.9%) in group A and 9 (30.0%) in group B (p < 0.05). On day 60, there was no difference between
group A and B, with response rates of 84.4% (n = 76) and 80.0% (n = 24) respectively (p > 0.05).
On day 90 there was no difference between group B and group A; with 26 (86.7%) and 79 (87.7%)
responders respectively. In both groups those with Anti-HBs levels <10 mIU/ml-1 attained
protective levels by day 180.
Conclusion: In this study, the three-week vaccination provided protective antibody titers within
a shorter time compared to the classic schedule. Therefore, in order to provide rapid antibody
production against hepatitis B virus, the accelerated vaccination schedule seems to be a good
preference.
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Hepatitis B virus infection is a common viral disease,
which constitutes a serious health issue throughout the
world due to its morbidity, mortality and economical
losses. It is estimated that there are 400–500 million
chronically infected people on this globe [1]. In endemic
areas hepatitis B is an important cause of mortality and is
the main cause of hepatocellular carcinoma and cirrhosis,
which are preventable by vaccination against hepatitis B.
Effective treatment for chronic hepatitis B has not been
established yet.
Vaccination against hepatitis B prevents not only the mor-
bidity and mortality due to acute viral disease, but also
chronic hepatitis B and its ultimately fatal complications
[2]. Currently two different immunization schedules have
been recommended for the recombinant vaccine: Repeat
doses at months 1 and 6 or 1, 2 and 12 after the first dose
[3]. By immunization seroprotection rate has been deter-
mined as 95–99% [4].
In such instances as living with a hepatitis B positive per-
son or being a health care worker, it is desirable to acquire
protection as quickly as possible. This study was designed
to compare the effectiveness for early and late antibody
response to the hepatitis B vaccine administered on days
10, 21 and 365 after the first dose versus the classic four-
dose vaccination schedule.
Subjects and Methods
This study was carried out during a one-year study period
in the Clinical Bacteriology and Infectious Disease
Department of the Medical Faculty of Çukurova Univer-
sity. One hundred and forty five subjects who were nega-
tive for HBsAg, Anti-HBs, Anti-HBc tests were enrolled.
Twenty five subjects were excluded because they were lost
to follow-up. The remaining 120 subjects, who were
healthy volunteers and had no history of vaccination for
hepatitis B, were included.
Individuals with a known immune deficiency condition
(eg: HIV positivity), diabetes mellitus, chronic renal fail-
ure, pregnancy, age above 60 years, children under age 2
years, and those with histories of occupational exposure
were excluded from the study. In group A family members
of hepatitis B carriers and health personnel agreeing to
join the study were included while in B group healthy
individuals without any history of exposure who reported
for vaccination against hepatitis B were included.
After approval, participants were assigned to either a
three-week schedule (on days 10 and 21 after the first
dose) as group A or the standard schedule (on month 1
and 2, after the first dose) as group B. For each individual
in the standard Group B, three subjects were enrolled into
group A. The recombinant hepatitis B vaccine (Gen-Hevac
B, Pasteur) was given as 20 µg intramuscular injections via
the deltoid muscle. The booster dose on day 365 was
planned for each group. The local ethics committee
approval was obtained for the study.
Anti-HBs levels were detected in serum samples of sub-
jects obtained on days 30, 60 and 90 after the first vacci-
nation. Subjects whose antibody titers failed to reach the
seroprotective level on day 90 were retested on day 180.
HBsAg, Anti-HBc and Anti-HBs levels were determined by
EIA (Abbott, AuxSYMSys).
The geometric average of the Anti-HBs levels in both
groups, on days 30, 60 and 90 after the first vaccination
were determined. The protective level of Anti-HBs was
defined as titers ≥10 mIU/ml. The results were evaluated
using the Fisher's exact test and geometric mean titers
were compared using the Wilcoxon test. Results are given
with a 95% confidence level.
Results
Group A consisted of 90 subjects, 50 (55.6%) female and
40 (44.4%) male, with an average age of 25.91 ± 11.92
years. There were 30 subjects in group B, 16 (53.3%)
female and 14 (46.7%) male, with an average age of 22.53
± 9.30 years. There was no significant statistical difference
in age or sex between the two groups (p > 0.05).
Of all subjects, health care workers accounted for 23.3%
of group A and 40% of group B (p < 0.05).
After three doses of vaccine, the Anti-HBs titers reached
protective levels in both groups. The rate of vaccinees who
had seroprotective levels of Anti-HBs (≥10 mIU/ml) on
day 30 was 53 (58.9%) in group A and 9 (30.0%) in group
B (p < 0.05). On day 60, there was no significant differ-
ence between group A and B, with rates of response at
84.4% (n = 76) and 80.0% (n = 24) respectively (p >
0.05). On day 90 there was no difference between group
B and group A; 86.7% (n = 26) vs 87.7% (n = 79) (Table
1). Serum samples taken on day 180 indicated that protec-
tive antibody titers were attained in subjects of both
groups, who had titers <10 mIU/ml-1 on day 90. With the
booster dose (on day 365), Anti-HBs levels were over 100
mIU/ml in 60 and >1000 mIU/ml in only 12 subjects (6
from each group). In both groups there was no statistically
significant difference in the antibody titers between males
and females (p > 0.05).
The geometric average was estimated as 33.3, 72.4, 81.6
for group A, and 12.2, 55.8, 118.8 for group B on days 30,
60 and 90, respectively.Page 2 of 4
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and accelerated hepatitis B vaccinations are shown in
table 1.
Discussion
Immunization of susceptible persons against hepatitis B is
necessary to prevent not only acute disease but also the
carrier and chronic states of hepatitis B infection. The ini-
tial immune response to hepatitis B vaccines following the
basic immunization series is an important determinant of
the duration of immunity. Clinical trials have demon-
strated the safety and efficacy of the hepatitis B vaccine
[3,4].
Increasing the dose of vaccine, administering the inocula-
tion intramuscularly and giving the vaccine more fre-
quently can enhance the immune response. Although
dose and intervals of hepatitis B vaccine is standardized,
the schedule chosen for administering the vaccine also
influences the antibody response [3]. Different acceler-
ated schedules for hepatitis vaccination B has been used in
neonates, immune competent adults or special hosts such
as liver transplant candidates or alcoholic patients. Several
studies have demonstrated that the accelerated schedule
provides not only sufficient but also rapidly rising anti-
body levels for hepatitis B protection [5-17].
Immunization studies with normal hosts showed good
response by the accelerated schedule. Orsolini and Gold-
farb reported more rapid and comparatively high seropro-
tection rates with the conventional schedule in neonates
[5,6]. Wahl noticed significantly higher protective anti-
body levels against Hepatitis B two weeks after the second
dose of vaccine in the short interval vaccination and that
all the vaccinees of this short interval vaccination schedule
had seroconverted within two months. In addition Wahl
noticed a more rapid achievement of the protective anti-
body levels. These findings led to the suggestion that the
accelerated schedule could provide protective antibody
levels earlier enough for especially those individuals at a
high risk for HBV exposure [7]. Wilkinson et al investi-
gated antibody levels among medical students and indi-
viduals at high risk and found that levels above 100 mIU/
L were effective in the accelerated vaccination schedule
[8]. In a five-year study, Belloni et al reported that there is
no difference in antibody levels between the traditional
and accelerated schedules at the end of the vaccination
[9].
A few articles have been reported on patients with under-
lying immunological disorders who failed to produce pro-
tective antibody levels. In four different studies performed
on alcoholic patients, hemophiliacs and liver transplant
candidates, protective antibody levels could not be
attained by the accelerated vaccination schedule probably
due to the low responsiveness to immunization in these
special hosts [10-13].
In the present study, on day 30, seroprotection of the vac-
cinees was 58.9% in group A and 30.0% in group B. Mar-
chou et al and Kaya et al. have stated similar rates for both
schedules [14,15]. In two different studies, Harries and
Wahl reported seroprotection rates of 40% and 48%
respectively, one month afterwards in an accelerated
immunization schedule. Results of these studies indicate
that the accelerated vaccination schedule could provide
early protective immunity [7,16].
In our study, the Anti-HBs levels on day 60 in both groups
were similar. The antibody titers provided by the classic
schedule were similar to those by the three-week schedule
on day 90 with no statistically significant differences
between the two groups
Marchou et al reported similar results on two schedules in
two different studies. In the two studies, one on chimpan-
zees by Ivarson et al and the other on humans by Wahl,
the six-week schedule was found to be successful in post-
exposure prophylaxis [7,17].
On day 90 eleven cases in group A and four cases in group
B were found to have anti-HBs titers <10 IU. No case with
levels below the protective level was found in both groups
on day 180. Marchou et al has reported early and persist-
ent protective immunity through accelerated schedule.
Table 1: Comparison of the AntiHBs responses after accelerated (A) and traditional (B) hepatitis B vaccination.
Day 30 Day 60 Day 90 Day 180
Group A Group B p Group A Group B p Group A Group B p Group A Group B p
AntiHBs < 10 mIUml-1 (%) 41.1 70.0 0.05 15.6 20.0 NS 12.3 13.3 NS - -
AntiHBs ≥ 10 mIU ml-1 (%) 58.9 30.0 0.05 84.4 80.0 NS 87.7 86.7 NS 100 100 NS
AntiHBs GMT (CL) 33.3 12.2 72.4 55.8 81.6 118.8
GMT: Geometric mean titer CI: 95% confidence interval NS: Not significantPage 3 of 4
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Besides they suggested application of the booster dose
both schedules [14,18].
The geometric mean of antibody titers varied depending
on the group selected for analysis. For example, all sub-
jects or only responders at specifically designated anti-
HBs levels. In this study, all subjects were investigated for
the geometric mean titer.
In conclusion, in our study, the three-week vaccination
provided protective antibody titers within a shorter time
compared to the classic schedule. On follow-up, antibody
titers were similar in both groups. It may be suggested that
the accelerated dose vaccination protocol could be used
for persons under high risk, such as family members of a
hepatitis B virus carrier or health care workers or those
wishing to travel to regions with high hepatitis B
prevalence.
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